Monte Rosa Therapeutics Debt-to-Equity Ratio Growth & History (GLUE)

Monte Rosa Therapeutics's debt-to-equity ratio was 0.17 for fiscal 2025.

View full Monte Rosa Therapeutics company overview

Monte Rosa Therapeutics annual debt-to-equity ratio history

Monte Rosa Therapeutics annual debt-to-equity ratio

Fiscal yearPeriod endedDebt-to-equity ratioChangeGrowth
20252025-12-310.17−0.02−12.23%
20242024-12-310.19−0.07−25.40%
20232023-12-310.260.08+48.32%
20222022-12-310.170.17
20212021-12-310.00

Monte Rosa Therapeutics debt-to-equity ratio trends

Between the periods ended 2021-12-31 and 2025-12-31, Monte Rosa Therapeutics's debt-to-equity ratio increased from 0.00 to 0.17, a change of 0.17. The latest reported quarter, Q2 2026, shows 0.08.

About the metric

What the debt-to-equity ratio means

The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.

Calculation and source

How debt-to-equity is calculated

TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Monte Rosa Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about GLUE yet. Start the conversation.

Write the first post